bbeadeec-bb57-4762-8828-3bd1696748fb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.450
- MYC_TARGETS_V2+0.370
- G2M_CHECKPOINT+0.340
- PROTEIN_SECRETION+0.320
- OXIDATIVE_PHOSPHORYLATION+0.310
- FATTY_ACID_METABOLISM+0.280
- ADIPOGENESIS+0.250
- PEROXISOME+0.240
- BILE_ACID_METABOLISM+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- ANGIOGENESIS-0.510
- TNFA_SIGNALING_VIA_NFKB-0.500
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.460
- INFLAMMATORY_RESPONSE-0.450
- IL6_JAK_STAT3_SIGNALING-0.440
- PANCREAS_BETA_CELLS-0.420
- APICAL_JUNCTION-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0H0-01A-11R-A056-07 | — | B | 0.960 |
| 2 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.934 |
| 3 | e7f9aa2a-9c1b-4c63-953b-4922fafd9150 | — | — | 0.925 |
| 4 | DRR168570 | — | — | 0.918 |
| 5 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.916 |
| 6 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.912 |
| 7 | TCGA-86-7955-01A-11R-2187-07 | — | cohortA4 | 0.911 |
| 8 | SRR8518295 | — | E | 0.906 |
| 9 | R6 | — | — | 0.904 |
| 10 | TCGA-ZF-A9RM-01A-11R-A38B-07 | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |